Allurion began training and onboarding partner accounts across the U.S., including academic medical centers and private practices. The company started manufacturing an FDA-approved product and expects to begin shipping in April. As part of its U.S. launch strategy, Allurion is exploring partnerships with self-insured employers to support benefit coverage for eligible employees and families. Employer-sponsored coverage includes about 165 million Americans, and GLP-1 medications account for 11% of employer insurance claims.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allurion Technologies Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603110900BIZWIRE_USPR_____20260311_BW346726) on March 11, 2026, and is solely responsible for the information contained therein.
Comments